2-week Evaluation of Marketed Silicone Hydrogel Contact Lenses in Indian Population

Johnson & Johnson (J&J)

Status: Completed

Conditions: Visual Acuity

Treatments: Device: senofilcon A; Device: lotrafilcon B

Study type: Interventional

Funder types: Industry

Identifiers

NCT02394808

CR-5625

Details and patient eligibility

About

The primary objective of this study is to evaluate the clinical performance of two marketed silicone hydrogel contact lenses in an Indian population in the following areas: physiological characteristics, comfort characteristics and vision characteristics.

Enrollment: 54 patients

Sex: All

Ages: 18 to 39 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. The subject must read, understand English, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. The subject must be 18 and less than 40 years of age.
4. The subject's corrected spherical equivalent distance refraction must be in the range of -1.00 to -5.00D in each eye with visual acuity of 20/25 provided study lenses in each eye.
5. The subject must have less than -1.00 D of cylindrical refraction.
6. The subject must have best corrected visual acuity of 20/25 or better in each eye.
7. The subject must be an adapted soft contact lens wearer in both eyes.
8. The subject must have normal eyes.

Exclusion criteria

1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued)
2. Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
3. Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
4. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia.
5. Any previous, or planned ocular or interocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.).
6. Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g. past peripheral ulcer, or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
7. Any ocular infections
8. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
9. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment
10. History of binocular vision abnormality or strabismus.
11. Any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV) by self report.
12. Employee of the investigational clinic (e.g. investigator, Coordinator, Technician)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

54 participants in 2 patient groups

Test Lens 1

Experimental group

Description:

senofilcon A (Approved contact lens material)

Treatment:

Device: senofilcon A

Device: lotrafilcon B

Test Lens 2

Active Comparator group

Description:

lotrafilcon B (Approved contact lens material)

Treatment:

Device: senofilcon A

Device: lotrafilcon B